Research ArticleCancer
High-throughput sequencing of the T cell receptor β gene identifies aggressive early-stage mycosis fungoides
- View ORCID ProfileAdele de Masson1,*,
- View ORCID ProfileJohn T. O’Malley1,*,
- Christopher P. Elco1,
- Sarah S. Garcia1,
- View ORCID ProfileSherrie J. Divito1,
- View ORCID ProfileElizabeth L. Lowry1,
- Marianne Tawa1,
- David C. Fisher2,
- Phillip M. Devlin3,
- Jessica E. Teague1,
- Nicole R. Leboeuf1,
- Ilan R. Kirsch4,
- View ORCID ProfileHarlan Robins4,
- View ORCID ProfileRachael A. Clark1,†,‡ and
- View ORCID ProfileThomas S. Kupper1,†,‡
- 1Department of Dermatology, Brigham and Women’s Hospital, and the Center for Cutaneous Oncology, Dana-Farber/Brigham and Women’s Cancer Center, Harvard Medical School, Boston, MA 02115, USA.
- 2Center for Hematologic Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA.
- 3Department of Radiation Oncology, Dana-Farber/Brigham and Women’s Cancer Center, Harvard Medical School, Boston, MA 02115, USA.
- 4Adaptive Biotechnologies, Seattle, WA 98102, USA.
- ↵‡Corresponding author. Email: tkupper{at}bwh.harvard.edu (T.S.K.); rclark{at}bwh.harvard.edu (R.A.C.)
See allHide authors and affiliations
Science Translational Medicine 09 May 2018:
Vol. 10, Issue 440, eaar5894
DOI: 10.1126/scitranslmed.aar5894
Vol. 10, Issue 440, eaar5894
DOI: 10.1126/scitranslmed.aar5894
Adele de Masson
1Department of Dermatology, Brigham and Women’s Hospital, and the Center for Cutaneous Oncology, Dana-Farber/Brigham and Women’s Cancer Center, Harvard Medical School, Boston, MA 02115, USA.
John T. O’Malley
1Department of Dermatology, Brigham and Women’s Hospital, and the Center for Cutaneous Oncology, Dana-Farber/Brigham and Women’s Cancer Center, Harvard Medical School, Boston, MA 02115, USA.
Christopher P. Elco
1Department of Dermatology, Brigham and Women’s Hospital, and the Center for Cutaneous Oncology, Dana-Farber/Brigham and Women’s Cancer Center, Harvard Medical School, Boston, MA 02115, USA.
Sarah S. Garcia
1Department of Dermatology, Brigham and Women’s Hospital, and the Center for Cutaneous Oncology, Dana-Farber/Brigham and Women’s Cancer Center, Harvard Medical School, Boston, MA 02115, USA.
Sherrie J. Divito
1Department of Dermatology, Brigham and Women’s Hospital, and the Center for Cutaneous Oncology, Dana-Farber/Brigham and Women’s Cancer Center, Harvard Medical School, Boston, MA 02115, USA.
Elizabeth L. Lowry
1Department of Dermatology, Brigham and Women’s Hospital, and the Center for Cutaneous Oncology, Dana-Farber/Brigham and Women’s Cancer Center, Harvard Medical School, Boston, MA 02115, USA.
Marianne Tawa
1Department of Dermatology, Brigham and Women’s Hospital, and the Center for Cutaneous Oncology, Dana-Farber/Brigham and Women’s Cancer Center, Harvard Medical School, Boston, MA 02115, USA.
David C. Fisher
2Center for Hematologic Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA.
Phillip M. Devlin
3Department of Radiation Oncology, Dana-Farber/Brigham and Women’s Cancer Center, Harvard Medical School, Boston, MA 02115, USA.
Jessica E. Teague
1Department of Dermatology, Brigham and Women’s Hospital, and the Center for Cutaneous Oncology, Dana-Farber/Brigham and Women’s Cancer Center, Harvard Medical School, Boston, MA 02115, USA.
Nicole R. Leboeuf
1Department of Dermatology, Brigham and Women’s Hospital, and the Center for Cutaneous Oncology, Dana-Farber/Brigham and Women’s Cancer Center, Harvard Medical School, Boston, MA 02115, USA.
Ilan R. Kirsch
4Adaptive Biotechnologies, Seattle, WA 98102, USA.
Harlan Robins
4Adaptive Biotechnologies, Seattle, WA 98102, USA.
Rachael A. Clark
1Department of Dermatology, Brigham and Women’s Hospital, and the Center for Cutaneous Oncology, Dana-Farber/Brigham and Women’s Cancer Center, Harvard Medical School, Boston, MA 02115, USA.
Thomas S. Kupper
1Department of Dermatology, Brigham and Women’s Hospital, and the Center for Cutaneous Oncology, Dana-Farber/Brigham and Women’s Cancer Center, Harvard Medical School, Boston, MA 02115, USA.
